Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

Dollar change +0.08
Percentage change 1.48	%

Peers: CHD BMRN PRGO AUPH NBTX ACET PLX GALT SCYX MNOV

| Held by: IWM VTI VXF IWO VTWO IWC GSSC VTWG RSSL EES

Index	RUT	P/E	290.48	EPS (ttm)	0.02	Insider Own	36.68%	Shs Outstand	76.03M	Perf Week	-10.29%
Market Cap	425.54M	Forward P/E	41.43	EPS next Y	0.13	Insider Trans	-0.20%	Shs Float	48.36M	Perf Month	-26.80%
Income	1.49M	PEG	-	EPS next Q	0.02	Inst Own	23.28%	Short Float	4.13%	Perf Quarter	46.79%
Sales	91.67M	P/S	4.64	EPS this Y	157.14%	Inst Trans	-9.10%	Short Ratio	1.59	Perf Half Y	115.29%
Book/sh	0.45	P/B	12.14	EPS next Y	231.25%	ROA	2.70%	Short Interest	2.00M	Perf Year	283.92%
Cash/sh	0.42	P/C	13.13	EPS next 5Y	-	ROE	4.82%	52W Range	1.36 - 7.97	Perf YTD	283.92%
Dividend Est.	-	P/FCF	107.19	EPS past 5Y	35.83%	ROI	4.10%	52W High	-31.15%	Beta	2.21
Dividend TTM	-	Quick Ratio	2.35	Sales past 5Y	22.27%	Gross Margin	61.45%	52W Low	303.68%	ATR (14)	0.40
Dividend Ex-Date	-	Current Ratio	2.95	EPS Y/Y TTM	122.52%	Oper. Margin	3.98%	RSI (14)	33.96	Volatility	5.91% 5.87%
Employees	106	Debt/Eq	0.08	Sales Y/Y TTM	9.95%	Profit Margin	1.62%	Recom	1.00	Target Price	8.70
Option/Short	Yes / Yes	LT Debt/Eq	0.05	EPS Q/Q	289.06%	Payout	-	Rel Volume	0.96	Prev Close	5.41
Sales Surprise	6.44%	EPS Surprise	417.54%	Sales Q/Q	31.21%	Earnings	Oct 31 AMC	Avg Volume	1.26M	Price	5.49
SMA20	-18.63%	SMA50	-5.54%	SMA200	42.18%	Trades		Volume	1,204,944	Change	1.48%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-16-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-11-22	Downgrade	B. Riley Securities	Buy → Neutral	$6 → $2.40
Mar-08-22	Initiated	ROTH Capital	Buy	$7
Oct-16-19	Initiated	Oppenheimer	Outperform	$6
Feb-14-19	Initiated	B. Riley FBR	Buy	$7
Nov-27-17	Resumed	H.C. Wainwright	Buy	$6 → $8
Sep-25-17	Initiated	Ladenburg Thalmann	Buy	$7
Jan-03-17	Initiated	Rodman & Renshaw	Buy	$6

Dec-03-24 08:34AM	ChromaDex Named to the Inc. 2024 Best in Business List in the Health Products Category (Business Wire)
Nov-22-24 09:15AM	ChromaDex Corporation (CDXC) Hits Fresh High: Is There Still Room to Run? (Zacks)
Nov-14-24 08:32AM	ChromaDex's Patented Nicotinamide Riboside (NR) Ingredient, Niagen, Featured as the Hero Ingredient in Longevity.Technology's Inaugural Longevity Supplement (Business Wire)
Nov-08-24 12:00PM	What Makes ChromaDex (CDXC) a Strong Momentum Stock: Buy Now? (Zacks)
Nov-07-24 08:32AM	ChromaDex's Pharmaceutical-Grade Niagen IV Now Accessible at over 200 Restore Hyper Wellness Clinics Nationwide (Business Wire)
09:15AM	Loading…
Nov-05-24 09:15AM	ChromaDex Corporation (CDXC) Hit a 52 Week High, Can the Run Continue? (Zacks) +6.45%
Nov-01-24 11:02AM	ChromaDex Corp (CDXC) Q3 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ... (GuruFocus.com) +67.91%
Oct-31-24 05:15PM	ChromaDex (CDXC) Beats Q3 Earnings and Revenue Estimates (Zacks)
04:09PM	ChromaDex: Q3 Earnings Snapshot (Associated Press Finance)
04:04PM	ChromaDex Corporation Reports Third Quarter 2024 Financial Results (Business Wire)
Oct-30-24 09:20AM	ChromaDex Corp (CDXC) Q3 2024 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-28-24 08:32AM	ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 (Business Wire) +5.76%
Oct-24-24 08:32AM	ChromaDex to Report Third Quarter 2024 Financial Results on Thursday, October 31, 2024 (Business Wire)
Oct-23-24 08:34AM	ChromaDex to Participate in the 17th Annual LD Micro Main Event (Business Wire)
Oct-18-24 09:40AM	Are Medical Stocks Lagging ChromaDex (CDXC) This Year? (Zacks)
08:32AM	Loading…
Oct-15-24 08:32AM	Yasmeen Nkrumah-Elie, Ph.D., Global Director of External Research at ChromaDex, Honored with the Trailblazing Woman Award by Radicle Science and Council for Responsible Nutrition (CRN) (Business Wire)
Oct-09-24 05:18PM	ChromaDex Corp (CDXC) Q2 2024 Earnings Call Highlights: Revenue Growth and Strategic Challenges (GuruFocus.com) +5.85%
Sep-26-24 04:12PM	ChromaDex to Participate in a Fireside Chat at the Lytham Partners Fall 2024 Investor Conference (Business Wire)
09:40AM	Is ChromaDex (CDXC) Stock Outpacing Its Medical Peers This Year? (Zacks)
Sep-20-24 08:32AM	ChromaDex Appoints Ozan Pamir as Chief Financial Officer (Business Wire)
Sep-10-24 08:32AM	ChromaDex Announces Expansion of Pharmaceutical-Grade Niagen IV and Injection Offerings to Additional Leading Wellness Clinics (Business Wire)
Sep-09-24 08:34AM	ChromaDex Celebrates 25 Years of Innovation and Pioneering NAD+ Research for Healthy Aging Solutions (Business Wire)
Aug-23-24 08:34AM	ChromaDex to Participate in Renmark's Virtual Non-Deal Roadshow Series On Thursday, August 29, 2024 (Business Wire) +6.69%
Aug-19-24 08:32AM	ChromaDex Secures U.S. Patent for the Composition of Matter of Salt Forms of NMNH (Dihydronicotinamide Mononucleotide), a Precursor to NAD+ (Business Wire)
Aug-07-24 06:25PM	ChromaDex (CDXC) Reports Break-Even Earnings for Q2 (Zacks) -6.74% +9.51%
05:25PM	ChromaDex: Q2 Earnings Snapshot (Associated Press Finance)
04:04PM	ChromaDex Corporation Reports Second Quarter 2024 Financial Results (Business Wire)
Aug-05-24 08:32AM	ChromaDex to Present at Canaccord Genuitys 44th Annual Growth Conference (Business Wire)
Jul-24-24 08:34AM	ChromaDex to Report Second Quarter 2024 Financial Results on Wednesday, August 7, 2024 (Business Wire)
Jul-23-24 08:32AM	ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs) (Business Wire)
08:34AM	Loading…
Jul-22-24 08:34AM	ChromaDex Appoints Carlos Lopez as Senior Vice President, General Counsel (Business Wire) +7.03%
Jul-16-24 08:34AM	ChromaDex Announces Pharmaceutical-Grade Intravenous and Injectable Niagen Will Debut at Leading Wellness Clinics in August (Business Wire) +10.83%
Jul-01-24 08:32AM	ChromaDex to Join Russell 2000 Index (Business Wire)
Jun-24-24 08:32AM	Milestone Phase II Clinical Study Demonstrates Niagen, Patented Nicotinamide Riboside (NR), Improves Functional Mobility for Individuals with Peripheral Artery Disease (PAD) (Business Wire) -6.59%
Jun-13-24 08:32AM	ChromaDex to Launch Niagen+, the First-Of-Its-Kind Pharmaceutical-Grade Intravenous and Injectable Niagen (Patented Nicotinamide Riboside Chloride or NRC) (Business Wire) +5.61%
Jun-10-24 09:45AM	ChromaDex (CDXC) Up as Ataxia Candidate Gets Orphan Drug Tag (Zacks)
Jun-07-24 08:34AM	ChromaDex Receives Exclusive U.S. FDA Orphan Drug Designation (ODD) and Rare Pediatric (RPD) Disease Designation for Nicotinamide Riboside Chloride (NRC) for the Treatment of Ataxia Telangiectasia (AT) (Business Wire) +11.89%
Jun-04-24 08:32AM	ChromaDex to Participate in Renmarks Virtual Non-Deal Roadshow on Tuesday, June 11, 2024 (Business Wire)
May-23-24 08:34AM	ChromaDex to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024 (Business Wire)
May-22-24 08:32AM	ChromaDexs Niagen Wins Prestigious NutraIngredients EU Healthy Ageing Ingredient of the Year Award (Business Wire)
May-10-24 03:22PM	ChromaDex Corp (CDXC) Q1 2024 Earnings: Aligns with EPS Projections, Misses Revenue Estimates (GuruFocus.com)
May-09-24 02:34PM	ChromaDex Corporation (NASDAQ:CDXC) Q1 2024 Earnings Call Transcript (Insider Monkey) -8.09%
07:17AM	Q1 2024 Chromadex Corp Earnings Call (Thomson Reuters StreetEvents)
03:42AM	ChromaDex Corp (CDXC) Q1 2024 Earnings Call Transcript Highlights: Navigating Challenges and ... (GuruFocus.com)
May-08-24 08:58PM	CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024 (InvestorPlace)
05:04PM	ChromaDex: Q1 Earnings Snapshot (Associated Press Finance)
04:04PM	ChromaDex Corporation Reports First Quarter 2024 Financial Results (Business Wire)
Apr-30-24 08:32AM	ChromaDex's NIAGEN (Patented Nicotinamide Riboside, NR), the Most Efficient and High-Quality NAD+ Precursor, Featured in New Solgar Cellular Nutrition Cellular Energy Supplement (Business Wire)
Apr-25-24 08:34AM	ChromaDex Announces Nationwide Launch of Tru Niagen at The Vitamin Shoppe (Business Wire)
Apr-24-24 08:34AM	ChromaDex to Report First Quarter 2024 Financial Results on Wednesday, May 8, 2024 (Business Wire)
Apr-23-24 08:32AM	ChromaDex Announces Inaugural Major Grocery Debut of Tru Niagen at Sprouts Farmers Market (Business Wire) +15.25%
Mar-26-24 08:32AM	ChromaDex Announces Tru Niagen is Now Third-Party Verified Through the Alkemist Assured Transparency Program (Business Wire)
Mar-07-24 01:59PM	ChromaDex Corp (CDXC) Reports Encouraging Fiscal Year 2023 Results with Positive Adjusted EBITDA (GuruFocus.com) -8.05%
10:37AM	ChromaDex Corporation (NASDAQ:CDXC) Q4 2023 Earnings Call Transcript (Insider Monkey)
06:27AM	Q4 2023 Chromadex Corp Earnings Call (Thomson Reuters StreetEvents)
Mar-06-24 09:53PM	CDXC Stock Earnings: ChromaDex Beats Revenue for Q4 2023 (InvestorPlace)
04:04PM	ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2023 Results (Business Wire)
Feb-21-24 08:32AM	ChromaDex to Report Fourth Quarter 2023 Financial Results on Wednesday, March 6, 2024 (Business Wire)
Feb-05-24 08:32AM	ChromaDex to Participate in Renmarks Virtual Non-Deal Roadshow on Monday, February 12, 2024 (Business Wire)
Jan-26-24 04:08PM	ChromaDex to Present at the Lytham Partners 2024 Investor Select Conference (Business Wire)
Dec-20-23 09:04AM	ChromaDex Supports the US Military with its Industry Leading NAD+ Supplement, Tru Niagen (Business Wire)
Dec-12-23 10:30AM	Neurohacker Collective and ChromaDex Partner to Optimize Cellular Health with the Debut of Qualia NAD+ (PR Newswire)
Nov-30-23 08:34AM	A Milestone Phase I Randomized, Double-Blind Clinical Trial Demonstrates High-Dose Niagen, Patented Nicotinamide Riboside (NR), Supplementation Induces a Potent NAD+ Response and Is Associated With Mild Improvement in Parkinson's Disease (PD) (Business Wire)
Nov-15-23 08:32AM	Newly Published Phase II Clinical Study Demonstrates that Supplementation with Niagen, Patented Nicotinamide Riboside (NR), Elevates NAD+ Up to Fourfold, Improving Motor Coordination and Eye Movement in Ataxia Telangiectasia (AT) Patients (Business Wire) +9.49%
Nov-10-23 12:54PM	ChromaDex Corporation (NASDAQ:CDXC) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-09-23 08:32AM	ChromaDex to Participate in Renmarks Virtual Non-Deal Roadshow on Tuesday, November 14, 2023 (Business Wire) -11.25%
Nov-08-23 06:33PM	ChromaDex Corp (CDXC) Reports Growth in Net Sales and Positive Adjusted EBITDA in Q3 2023 (GuruFocus.com)
04:48PM	ChromaDex: Q3 Earnings Snapshot (Associated Press Finance)
04:02PM	ChromaDex Corporation Reports Third Quarter 2023 Financial Results (Business Wire)
Nov-01-23 08:34AM	ChromaDex Debuts Clinical Strength Tru Niagen Pro 1,000mg Featuring Niagen (Patented Nicotinamide Riboside), One of the Most Efficient Nicotinamide Adenine Dinucleotide (NAD+) Boosters Available, to Consumers Nationwide (Business Wire)
Oct-31-23 08:34AM	ChromaDex to Report Third Quarter 2023 Financial Results on Wednesday, November 8, 2023 (Business Wire)
Oct-26-23 08:32AM	ChromaDex and Zesty Paws Crack the Code on Cellular Health for Dogs With Healthy Aging Line (Business Wire)
Oct-02-23 08:32AM	A Milestone Clinical Study Reveals that Elevating Nicotinamide Adenine Dinucleotide (NAD+) with Nicotinamide Riboside (NR) Supplementation Effectively Reduces Inflammation in Both Healthy Subjects and Immune Cells Derived from Psoriasis Patients (Business Wire)
Aug-24-23 08:32AM	Preclinical Study Builds on Growing Body of Evidence Showcasing Exogenous Nicotinamide Mononucleotide (NMN) Must be Converted to Nicotinamide Riboside (NR), Making NR a More Efficient Nicotinamide Adenine Dinucleotide (NAD+) Precursor to NMN (Business Wire)
Aug-12-23 09:04AM	Analysts Expect Breakeven For ChromaDex Corporation (NASDAQ:CDXC) Before Long (Simply Wall St.)
Aug-10-23 10:38AM	Q2 2023 Chromadex Corp Earnings Call (Thomson Reuters StreetEvents)
Aug-09-23 05:40PM	ChromaDex (CDXC) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:37PM	ChromaDex: Q2 Earnings Snapshot (Associated Press Finance)
04:02PM	ChromaDex Corporation Reports Second Quarter 2023 Financial Results (Business Wire)
Aug-08-23 08:34AM	ChromaDex Launches Tru Niagen® with iHerb, the Worlds Number One Online Destination for Health and Wellness (Business Wire)
Aug-07-23 08:32AM	ChromaDex to Participate in Renmarks Virtual Non-Deal Roadshow Series (Business Wire)
Aug-02-23 08:02AM	ChromaDex to Report Second Quarter 2023 Financial Results on Wednesday, August 9, 2023 (Business Wire)
Jul-18-23 08:32AM	Findings from Published Abstracts Showcase the Importance of Nicotinamide Adenine Dinucleotide (NAD+) in Glaucoma Patients and that Supplementation with Nicotinamide Riboside (NR) Demonstrate Promising Effects (Business Wire)
Jun-16-23 08:32AM	ChromaDex, a Global Authority on Nicotinamide Adenine Dinucleotide (NAD+), Celebrates the 10th Anniversary of its ChromaDex External Research Program (CERP), the Industry Leading Research Program Advancing the Science of NAD+ and Healthy Aging (Business Wire)
Jun-08-23 08:19AM	It's A Story Of Risk Vs Reward With ChromaDex Corporation (NASDAQ:CDXC) (Simply Wall St.)
May-30-23 08:34AM	ChromaDex to Participate in the LD Micro Invitational XIII (Business Wire)
May-11-23 08:34AM	ChromaDex to Present at the Lytham Partners Spring 2023 Investor Conference (Business Wire)
May-10-23 05:35PM	ChromaDex (CDXC) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +6.14%
04:32PM	ChromaDex: Q1 Earnings Snapshot (AP Finance)
04:02PM	ChromaDex Corporation Reports First Quarter 2023 Financial Results (Business Wire)
May-02-23 08:32AM	ChromaDex to Report First Quarter 2023 Financial Results on Wednesday, May 10, 2023 (Business Wire)
06:31AM	We Think ChromaDex (NASDAQ:CDXC) Can Afford To Drive Business Growth (Simply Wall St.)
Apr-12-23 01:04PM	Individual investors account for 44% of ChromaDex Corporation's (NASDAQ:CDXC) ownership, while insiders account for 26% (Simply Wall St.)
Mar-27-23 06:43AM	Bullish ChromaDex Corporation (NASDAQ:CDXC) insiders filled their treasuries with US$1.6m worth of stock over last year (Simply Wall St.)
Mar-10-23 05:23AM	ChromaDex Full Year 2022 Earnings: EPS Misses Expectations (Simply Wall St.) -9.76%
02:28AM	ChromaDex Corporation (NASDAQ:CDXC) Q4 2022 Earnings Call Transcript (Insider Monkey)
Mar-09-23 09:06AM	Q4 2022 Chromadex Corp Earnings Call (Thomson Reuters StreetEvents) -10.38%
Mar-08-23 06:25PM	ChromaDex (CDXC) Reports Q4 Loss, Lags Revenue Estimates (Zacks) +12.96%
04:02PM	ChromaDex Corporation Reports Fourth Quarter and Fiscal Year 2022 Results (Business Wire)
Mar-06-23 08:34AM	ChromaDex to Participate at the 35th Annual ROTH Capital Partners Conference on March 13, 2023 (Business Wire)

Chromadex Corp. is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company's patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen. It operates through the following segments: Consumer Products, Ingredients, and Analytical Reference Standards and Services. The Consumer Products segment provides finished dietary supplement products that contain the firm's proprietary ingredients directly to consumers as well as to distributors. The Ingredients segment supplies ingredients as raw materials to the manufacturers of consumer products. The Analytical Reference Standards and Services segment includes supply of phytochemical reference standards and other research and development services. The company was founded by Mark S. Germain and Frank L. Jaksch, Jr. in 1999 and is headquartered in Los Angeles, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Jaksch Frank L Jr	Director	Dec 13 '24	Option Exercise	3.66	50,001	183,004	281,340	Dec 13 07:12 PM
Jaksch Frank L Jr	Director	Dec 13 '24	Sale	6.19	37,161	229,956	244,179	Dec 13 07:12 PM
Frank Jaksch Jr.	affiliate	Dec 13 '24	Proposed Sale	6.19	37,161	229,961		Dec 13 01:54 PM
Pamir Ozan	Chief Financial Officer	Nov 22 '24	Buy	7.36	2,907	21,397	2,907	Nov 25 07:28 AM
Patrick Kristin	Director	Aug 23 '24	Option Exercise	1.67	23,000	38,320	23,000	Aug 26 07:06 PM
Patrick Kristin	Director	Aug 23 '24	Sale	3.57	23,000	82,110	0	Aug 26 07:06 PM
Kristin Patrick	affiliate	Aug 23 '24	Proposed Sale	3.69	23,000	84,810		Aug 23 11:52 AM

Open in Screener

ATNF

180 Life Sciences Corp

Dec 20 • 04:00PM ET

1.86

Dollar change -0.08
Percentage change -4.12	%

Healthcare • Biotechnology • USA • NASD

ATNF 180 Life Sciences Corp daily Stock Chart

Peers: AMGN REGN BIIB ABBV VRTX GILD BMRN INCY ALNY NBIX

| Held by: VXF

Index	-	P/E	-	EPS (ttm)	-4.81	Insider Own	4.35%	Shs Outstand	1.03M	Perf Week	-3.63%
Market Cap	3.53M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	0.51M	Perf Month	-20.51%
Income	-3.12M	PEG	-	EPS next Q	-	Inst Own	14.55%	Short Float	12.70%	Perf Quarter	0.00%
Sales	0.00M	P/S	-	EPS this Y	-	Inst Trans	16.44%	Short Ratio	0.03	Perf Half Y	24.83%
Book/sh	3.64	P/B	0.51	EPS next Y	-	ROA	-40.47%	Short Interest	0.06M	Perf Year	-44.69%
Cash/sh	0.10	P/C	18.57	EPS next 5Y	-	ROE	-174.19%	52W Range	1.16 - 17.75	Perf YTD	-54.15%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-	ROI	-83.37%	52W High	-89.52%	Beta	-
Dividend TTM	-	Quick Ratio	0.19	Sales past 5Y	0.00%	Gross Margin	-	52W Low	60.34%	ATR (14)	0.29
Dividend Ex-Date	-	Current Ratio	0.19	EPS Y/Y TTM	98.21%	Oper. Margin	-	RSI (14)	38.40	Volatility	9.94% 10.16%
Employees	4	Debt/Eq	0.13	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	1520.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	96.52%	Payout	-	Rel Volume	0.03	Prev Close	1.94
Sales Surprise	-	EPS Surprise	84.62%	Sales Q/Q	-	Earnings	-	Avg Volume	2.01M	Price	1.86
SMA20	-10.81%	SMA50	-35.02%	SMA200	-15.79%	Trades		Volume	51,471	Change	-4.12%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-15-21	Initiated	Maxim Group	Buy	$11

Dec-12-24 08:00AM	180 Life Sciences Corp. Regains Full Compliance with Nasdaq Continued Listing Rules (ACCESSWIRE) -14.16%
Dec-04-24 08:00AM	180 Life Sciences Corp. Announces the Appointment of Stephen Shoemaker to Board of Directors (ACCESSWIRE)
Oct-31-24 08:00AM	180 Life Sciences Corp. Retains Senior Technology Consultant and Commences Gaming Technology Platform Integration (ACCESSWIRE)
Oct-29-24 08:00AM	180 Life Sciences Corp. Appoints Mr. Jay Goodman to Board of Directors (ACCESSWIRE)
Oct-25-24 09:00AM	Elray Resources Announces Strategic Sale of Crypto iGaming Technology (GlobeNewswire) +9.79%
10:52AM	Loading…
Oct-17-24 10:52AM	180 Life Sciences' Brave Decision To Switch to the iGaming Industry (GuruFocus.com) -33.08%
Oct-16-24 08:00AM	180 Life Sciences Corp. Interim CEO, Blair Jordan, Issues Letter to Stockholders; Provides Update on Newly Acquired Gaming Technology Platform (ACCESSWIRE) +325.66%
Oct-09-24 08:30AM	180 Life Sciences Corp. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Rule and Expands into the Global iGaming Sector (ACCESSWIRE) +16.10%
Oct-03-24 08:30AM	180 Life Sciences Corp. - Corporate Updates (ACCESSWIRE)
Sep-12-24 04:15PM	180 Life Sciences Announces the Appointment of Omar Jimenez as Chief Financial Officer (GlobeNewswire) +13.64% -9.50%
Jul-30-24 08:00AM	180 Life Sciences Announces Positive Topline Results of a Clinical Pharmacology Study Testing a New Solid Formulation of CBD with Enhanced Oral Uptake (GlobeNewswire)
Jul-23-24 08:00AM	180 Life Sciences Granted an Additional Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire)
Jul-02-24 08:30AM	180 Life Sciences Granted Extension by Nasdaq Hearing Panel to Regain Compliance with Continued Listing Requirements (GlobeNewswire) +10.00%
May-16-24 11:53AM	ATNF Stock Earnings: 180 Life Sciences Reported Results for Q1 2024 (InvestorPlace) -14.95%
Mar-14-24 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire)
07:00AM	Loading…
Feb-26-24 07:00AM	180 Life Sciences Corp. Announces 1-For 19 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire) +5.49%
Dec-04-23 09:00AM	180 Life Sciences Engages Financial Advisor to Explore Strategic Alternatives (GlobeNewswire)
Nov-28-23 09:00AM	180 Life Sciences Announces Review of Strategic Alternatives (GlobeNewswire) +7.70%
Aug-14-23 04:29PM	180 Life Sciences Corp. Announces Closing of $3 Million Public Offering (GlobeNewswire)
Aug-10-23 08:46AM	180 Life Sciences Corp. Announces Pricing of $3 Million Public Offering (GlobeNewswire) -16.73%
Aug-07-23 09:00AM	180 Life Sciences Announces an Agreement for a Clinical Pharmacology Study Testing a New Formulation of CBD for Enhanced Oral Uptake (GlobeNewswire)
Aug-03-23 08:00AM	180 Life Sciences Provides Update on Regulatory Approval Process in the UK and US for Dupuytrens Disease Treatment; Continues Consultations with the UK MHRA and Initiates a Type C Meeting Request With the US FDA (GlobeNewswire)
Jul-31-23 08:00AM	180 Life Sciences Corp. Announces the Filing of a Provisional Patent Describing the Combination of CBD With GLP-1 Agonists to Suppress Appetite (GlobeNewswire)
Apr-10-23 04:30PM	180 Life Sciences Corp. Announces Closing of $3 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire)
Apr-05-23 01:00PM	180 Life Sciences Corp. Announces $3 Million Registered Direct Offering and Concurrent Private Placement (GlobeNewswire) -19.66%
Feb-27-23 08:30AM	180 Life Sciences Announces Presentation at the Gordon Conference (GlobeNewswire) +5.51%
Feb-23-23 07:30AM	180 Life Sciences Announces Allowance of Claims for a US Patent for Dupuytrens Disease Treatment and Application (GlobeNewswire) -10.82%
Feb-22-23 04:30PM	180 Life Sciences Provides Update Regarding Anti-TNF Frozen Shoulder Trial (GlobeNewswire)
Jan-25-23 08:45AM	180 Life Sciences Announces Publication of a Review on the Treatments for Early Stage Dupuytrens Disease (GlobeNewswire) +33.75%
Jan-17-23 08:00AM	180 Life Sciences Engages Kinexum for Assistance in Applying for Marketing Authorisation in the United Kingdom (GlobeNewswire)
08:30AM	Loading…
Jan-05-23 08:30AM	180 Life Sciences Regains Full Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +12.33%
Jan-04-23 08:30AM	180 Life Sciences Announces Publication of a Review on the Biological Basis of Dupuytrens Disease (GlobeNewswire) -17.36%
Dec-29-22 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders (GlobeNewswire) +13.86%
Dec-23-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -21.52%
Dec-20-22 02:11PM	180 Life Sciences Corp. Announces $6 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) -15.85%
Dec-16-22 09:00AM	180 Life Sciences Corp. Announces 1-for 20 Reverse Stock Split as Part of Nasdaq Compliance Plan (GlobeNewswire) -11.67%
Nov-30-22 05:00PM	180 Life Sciences Provides Update on Progress To Seek Medicines and Healthcare Products Regulatory Agency Marketing Authorization for Anti-TNF Treatment of Early Stage Dupuytrens Contracture (GlobeNewswire)
Nov-21-22 08:30AM	180 Life Sciences to Participate in A.G.P.s Virtual Biotech Conference to be Held November 30 December 1, 2022 (GlobeNewswire) -12.87%
Nov-15-22 12:37PM	CORRECTION: Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease (GlobeNewswire) +12.02%
08:00AM	Adalimumab Found To Be A Likely Cost-Effective Treatment for Early-Stage Dupuytrens Disease (GlobeNewswire)
Sep-26-22 08:30AM	180 Life Sciences Issues Letter to Stockholders (GlobeNewswire)
Aug-22-22 08:30AM	180 Life Sciences with the University of Oxford Announce the Enrollment of the First Patient in a Trial of Anti-TNF for People with Early-Stage Frozen Shoulder (GlobeNewswire) -10.53%
Jul-27-22 08:30AM	180 Life Sciences Announces That the University of Oxford Has Been Awarded a Grant From the National Institute for Health and Care Research in the U.K. to Conduct a Clinical Trial in Post Operative Delirium/Cognitive Deficit in a Jointly Funded Program With 180 Life Sciences Corp. (GlobeNewswire)
Jul-21-22 08:00AM	180 Life Sciences Corp. Announces Closing of $6.5 Million Registered Direct Offering (GlobeNewswire) +5.65%
Jul-18-22 08:30AM	180 Life Sciences Corp. Announces $6.5 Million Registered Direct Offering (GlobeNewswire)
Jun-22-22 04:05PM	180 Life Sciences Corp. Issues Letter to Stockholders (GlobeNewswire)
Jun-14-22 04:15PM	180 Life Sciences Provides Update on Correspondence Received from U.K. and U.S. Regulatory Authorities on Pathway for a Therapy That Could Prevent Progression of Early-Stage Dupuytrens Disease (GlobeNewswire) -34.00%
May-31-22 08:30AM	180 Life Sciences Begins Consultations with UK and US Regulatory Authorities on Pathway for a Therapy that Could Prevent Progression of Early-Stage Dupuytrens Disease (GlobeNewswire) +18.25%
May-02-22 08:00AM	REPEAT - 180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology (GlobeNewswire) -20.75%
Apr-29-22 06:32PM	180 Life Sciences and University of Oxford Announce Publication of Positive Phase 2b Dupuytrens Disease Study Results in The Lancet Rheumatology (GlobeNewswire) +22.54%
Feb-17-22 08:30AM	180 Life Sciences Corp. Forms Scientific Advisory Board (GlobeNewswire) -6.61%
Jan-31-22 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Shareholders (GlobeNewswire) +7.12%
Dec-28-21 11:00AM	180 Life Sciences Corp. To Participate in the Biotech Showcase 2022 Virtual Conference To be Held January 10-12, 2022 (GlobeNewswire) -5.75%
Dec-15-21 08:15AM	180 Life Sciences Corp. Enters into a License Agreement with University of Oxford for Regenerative Molecule HMGB1 for Liver Diseases (GlobeNewswire)
Dec-12-21 06:06AM	Insider Buying: The 180 Life Sciences Corp. (NASDAQ:ATNF) Lead Independent Director Just Bought 328% More Shares (Simply Wall St.)
Dec-10-21 05:15PM	180 Life Sciences Corp (ATNF) CEO James N. Woody Bought $53,375 of Shares (GuruFocus.com)
Dec-06-21 08:15AM	180 Life Sciences Provides Follow-Up Information on Oxford University and the Companys Successful Dupuytrens Phase 2b Clinical Trial Results (GlobeNewswire) +7.95%
Dec-01-21 02:45PM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal Presents Keynote Address at the 2021 International Dupuytren Symposium, Including Top Line Data From the Phase 2b Clinical Trial (GlobeNewswire) -20.85%
02:26PM	180 Life Sciences: Positive Data From Dupuytrens Disease Study Could Be a Big Catalyst, Says Analyst (TipRanks)
Nov-22-21 08:30AM	180 Life Sciences Corp. Expands Patent Portfolio (GlobeNewswire)
Nov-18-21 08:15AM	180 Life Sciences Corp. Co-Founder Prof. Jagdeep Nanchahal to Present a Keynote Address at the 2021 International Dupuytren Symposium (GlobeNewswire) +9.86%
Nov-03-21 12:06PM	180 Life Sciences Corp. Names Quan A. Vu Chief Operating Officer/Chief Business Officer (GlobeNewswire)
Oct-26-21 08:30AM	180 Life Sciences Corp. Publishes Pre-Clinical Study Report on the Effects of CBG Derivatives on Pain, Inflammation and Obesity in The Journal Molecules (GlobeNewswire)
Sep-30-21 08:30AM	180 Life Sciences Corp. Continues To Expand Intellectual Property Portfolio (GlobeNewswire) +5.66%
Sep-20-21 08:00AM	Celltrion Healthcare and 180 Life Sciences Enter Into Memorandum of Understanding for a Supply Agreement for the Ongoing Supply of Drug for Anti-TNF Product Trials for Novel Indications (GlobeNewswire) -6.29%
Aug-30-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Aug-24-21 08:30AM	180 Life Sciences Corp. Announces Closing of $15.0 Million Private Placement (GlobeNewswire)
Aug-19-21 09:00AM	180 Life Sciences Corp. Announces $15.0 Million Private Placement (GlobeNewswire) -25.73%
08:10AM	Is 180 Life Sciences Corp.'s (NASDAQ:ATNF) Shareholder Ownership Skewed Towards Insiders? (Simply Wall St.)
Aug-02-21 08:00AM	Chairman of the 180 Life Sciences Clinical Advisory Board, Professor Jagdeep Nanchahal, has Been Invited To Present a Keynote Talk at the British Society for Surgery of the Hand (BSSH) at the Autumn Scientific Meeting in Oxford UK on September 9, 2021 (GlobeNewswire)
Jul-29-21 08:00AM	180 Life Sciences to Participate in Fireside Chat at BTIG Virtual Biotechnology Conference (GlobeNewswire)
Jul-28-21 08:15AM	180 Life Sciences Announces Selection of Lead Synthetic CBD Analogue (GlobeNewswire)
Jul-20-21 08:00AM	180 Life Sciences Regains Nasdaq Compliance Under Listing Rule 5250(c)(1) (GlobeNewswire)
Jul-12-21 09:51AM	180 Life Sciences Regains Nasdaq Compliance for Listing Rules 5605(b)(1) and 5605(c)(2) (GlobeNewswire) +9.75%
Jul-07-21 08:00AM	180 Life Sciences Expands Scientific Fibrosis Platform with Collagen VI as a Driver and Disease Biomarker in Human Fibrosis Published in the FEBS Journal (GlobeNewswire)
Jun-28-21 08:15AM	180 Life Sciences Joins Russell Microcap® Index (GlobeNewswire)
08:00AM	180 Life Sciences Files Plan with Nasdaq Related to Delayed Quarterly Report on Form 10-Q and Form 10-K (GlobeNewswire)
Jun-10-21 09:12AM	180 Life Sciences Corp. Announces the Appointment of Pamela Marrone, PhD and Frank Knuettel II, MBA to Board of Directors (GlobeNewswire)
Jun-01-21 08:00AM	180 Life Sciences Corp. to Present at LD Micro Invitational XI (GlobeNewswire) +8.90%
May-28-21 08:00AM	180 Life Sciences Corp. Announces the Appointment of Russell T. Ray, MBA and Teresa DeLuca MD, MBA to Board of Directors (GlobeNewswire) +7.96%
May-21-21 04:45PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Quarterly Report on Form 10-Q (GlobeNewswire) +10.61%
Apr-20-21 08:00AM	180 Life Sciences Corp. Announces Collection of All Patient Data for Phase 2b Dupuytrens Disease Trial (GlobeNewswire)
Apr-19-21 05:00PM	180 Life Sciences Corp. Receives Expected Notification From Nasdaq Related To Delayed Annual Report on Form 10-K (GlobeNewswire) -16.53%
Apr-14-21 08:15AM	180 Life Sciences Corp. Congratulates Dr. Lynn Williams on International Dupuytren Award 2021 (GlobeNewswire)
Mar-26-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) Recognized R&D Pioneers in Anti-Inflammatory Therapeutics (GlobeNewswire) +18.57%
Mar-25-21 08:30AM	180 Life Sciences Corp. (NASDAQ: ATNF) in Hot Pursuit of New Anti-Inflammatory Blockbusters (GlobeNewswire) +13.65%
Mar-24-21 08:30AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Mar-08-21 01:30PM	180 Life Sciences Corp. to Present at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC (GlobeNewswire) +5.46%
Feb-24-21 04:00PM	180 Life Sciences Corp. Announces Closing of $11.7 Million Private Placement (GlobeNewswire) +11.06% -10.37%
Feb-19-21 09:00AM	180 Life Sciences Corp. Announces $11.7 Million Private Placement (GlobeNewswire) -13.46%
Feb-17-21 12:00AM	Do Insiders Own Lots Of Shares In 180 Life Sciences Corp. (NASDAQ:ATNF)? (Simply Wall St.) -5.45%
Jan-11-21 08:00AM	180 Life Sciences Corp. to Present at the Biotech Showcase(TM) Digital 2021 Conference (Newsfile) +5.06%
Jan-05-21 02:50PM	180 Life Sciences Corp. to Present at the H.C. Wainwright Bioconnect 2021 Conference (GlobeNewswire) +7.17%
Dec-03-20 11:08AM	180 Life Sciences Corp. to Present at the 13th Annual LD Micro Main Event Conference on Tuesday, December 15th at 1:40 PM EST (GlobeNewswire)
Nov-24-20 10:00AM	180 Life Sciences Corp. to Ring Nasdaq Opening Bell on November 27, 2020 (GlobeNewswire) -6.93%
Nov-23-20 08:30AM	180 Life Sciences Corp. Continues to Expand Intellectual Property Portfolio With Additional Patent Grants (GlobeNewswire) +17.44%
Nov-17-20 08:00AM	180 Life Sciences Corp. CEO James Woody, MD, PhD Issues Letter to Stockholders (GlobeNewswire)
Nov-10-20 11:46AM	180 Life Sciences Announces Completion of Transaction with KBLM Merger Corp IV (GlobeNewswire) -6.47%

180 Life Sciences Corp. operates as a clinical-stage biotechnology company, which engages in the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain by leveraging the combined expertise of luminaries in therapeutics from Oxford University, the Hebrew University and Stanford University. The company was founded by Marc Feldmann, Lawrence J. Steinman, and Jonathan B. Rothbard on September 7, 2016 and is headquartered in Palo Alto, CA.

CDXC

Chromadex Corp

ATNF

180 Life Sciences Corp

Upgrade your FINVIZ experience